维立志博-B：1项LBL-034临床研究获选在第67届ASH年会首日作第一个口头报告
LEADS BIOLABS-BLEADS BIOLABS-B(HK:09887) Zhi Tong Cai Jing·2025-11-03 22:44

Core Viewpoint - The company, Valiant Bio-B (09887), announced that five research abstracts have been selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH) [1] Group 1: Company Developments - The company provided further details regarding its innovative drugs LBL-034 and LBL-076, which have multiple research abstracts included in the ASH meeting [1] - One clinical study of LBL-034 has been selected for the first oral presentation on the first day of the conference, showcasing the latest efficacy and safety data for LBL-034 in patients with relapsed/refractory multiple myeloma [1]